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Background: Papillary thyroid carcinoma (PTC) is associated with a high incidence of regional node metastasis, but
the patterns of lateral neck node metastasis (LNM) vary. Occasionally, a solitary LNM (SLNM) is seen in PTC patients.
We therefore assessed whether selective single level node dissection is appropriate in PTC patients with SLNM.
Methods: We retrospectively reviewed the medical records of 241 PTC patients who underwent total
thyroidectomy with central neck dissection plus ipsilateral internal jugular node dissection (level II to IV) between
January 2010 and December 2011. Of these patients, 51 had SLNM and 190 had multiple LNM (MLNM). The
clinicopathologic characteristics of the two groups were compared.
Results: Age, gender ratio, and numbers of lateral neck nodes harvested (29.4 ± 11.0 versus 30.3 ± 9.5; P = 0.574)
were similar in the SLNM and MLNM groups. Mean primary tumor size was significantly smaller in the SLNM than in
the MNLM group (1.03 cm versus 1.35 cm; P = 0.037). The proportion of patients with primary tumor ≤ 1 cm was
significantly greater in the SLNM group (60.8% versus 38.4%; P = 0.006), whereas the proportion with maximal node
size ≤ 0.7 cm (28.9% versus 73.3%; P <0.001) and the proportion with capsular invasion (62.7% versus 83.7%,
P = 0.002) were significantly lower in the SLNM than in the MLNM group.
Conclusions: Selective single level neck dissection can be considered as an alternative to systemic lateral neck
dissection in PTC patients with SLNM, maximal metastatic node size ≤ 0.7 cm, and no extrathyroidal invasion.
Keywords: thyroid, papillary, solitary, metastasisBackground
Although regional lymph node metastasis is frequently
observed in patients with papillary thyroid carcinoma
(PTC), the patterns of lateral neck node metastasis (LNM)
have been found to vary [1-5]. Some patients with PTC
have solitary LNM (SLNM). LNM, whether solitary or
multiple, has been associated with an increased risk of re-
gional recurrence [1,4,6,7], and cervical lymph node recur-
rences have been reported in up to 31% of patients with
PTC [8]. To reduce the risk of recurrence, various types of
lateral neck dissection (LND) have been introduced in pa-
tients with clinically positive nodes [1,9,10]. Although
many surgeons in other countries do not perform prophy-
lactic LND, this method is preferred by Japanese surgeons
[11]. Less invasive neck dissection in PTC patients may* Correspondence: SURGHSC@yuhs.ac
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reproduction in any medium, provided the oravoid perioperative morbidity and improve patient quality
of life. Decisions regarding the extent of LND are usually
based on predictable metastatic patterns. Less invasive
neck dissection can be considered for patients with LNM
confined to a single node. In the present study, we evalu-
ated whether selective single level node dissection is ap-
propriate in PTC patients with SLNM.Methods
Approval to retrospectively review the images and medical
records of patients was obtained from the Institutional
Review Board of Gangnam Severance Hospital, Yonsei
University College of Medicine. In addition to approv-
ing the study protocol, the Institutional Review Board
required neither patient approval nor informed con-
sent for the review of records (#3-2012-0051).
Between 1 January 2010 and 31 December 2011, 656
PTC patients with LNM underwent surgery at the Thyroid. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Patient demographics and clinical characteristics
(n = 241)
Characteristics Results
Age (mean and range) 43.9 ± 12.5 (16 to 76)
≥ 45 years 108 (44.8%)
< 45 years 133 (55.2%)
Sex (male/female) 67/174 (27.8%/72.2%)
Tumor size (cm, mean) 1.28 ± 0.97
> 1 cm 137 (56.8%)
≤ 1 cm 104 (43.2%)
Multifocality
Yes/No 84 (34.9%)/157 (65.1%)
Bilaterality
Yes/No 44 (18.3%)/197 (81.7%)
Capsular invasion
Yes/No 191 (79.3%)/50 (20.7%)
Thyroiditis
Yes/No 71 (29.5%)/170 (70.5%)
Central compartment metastases 173 (71.8%)
Skip metastases 68 (28.2%)
Solitary lymph node involvement 51 (21.2%)
Maximal lymph node size
(cm, mean, and range)
0.91 ± 0.62 (0.01 to 3.8 cm)
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University College of Medicine, Korea. Patients were ex-
cluded if they had previously undergone thyroid surgery
or radiotherapy. They were also excluded if they had other
subtypes of PTC, other thyroid malignancies, bilateral thy-
roid cancer with bilateral neck node metastases, medias-
tinal metastasis, or other types of distant metastasis. Our
study cohort consisted of 241 patients with conventional
PTC who underwent total thyroidectomy with ipsilateral
internal jugular node dissection (level II to IV). We did
not include level V in patients with clinically negative level
V nodes.
All patients underwent preoperative ultrasonography
and/or neck computed tomography to evaluate the size
and location of the tumor and the presence of cervical
nodal metastases. Potential LNMs identified on preopera-
tive imaging were further investigated by fine-needle aspir-
ation biopsy, by measuring thyroglobulin concentrations
in fine-needle aspirates, and/or by intraoperative frozen
examination. Lateral neck nodes were classified into neck
levels (II to IV) based on the criteria of the American
Head and Neck Society [12].
Patients were divided according to the number of
LNM, as determined from postoperative histopathologic
records, into those with SLNM and those with multiple
LNM (MLNM). The clinicopathological features of the
two groups were compared, including patient sex and age;
tumor size, location, multiplicity, bilaterality, and encapsu-
lation; total number of retrieved lymph nodes; and max-
imal diameter of lateral neck nodes. Primary tumors were
classified as being located in the upper, middle, and lower
poles of the thyroid glands. When multiple foci were
found, the dominant nodule was regarded as the primary
carcinoma. Skip metastasis was defined as an LNM with
no positive nodes in the central compartment [2]. Each
node level was marked by the surgeon during LND.
Statistical analysis was performed using the Statistical
Package for Social Science (SPSS) version 18.0 for Windows
(SPSS, Inc, Chicago, IL, USA). Data in the two groups were
compared using Student’s t test, the chi-square test, and
Fisher’s exact test, as appropriate. Multiple logistic regres-
sion analysis was used to assess the statistical significance
of the associations between SLNM and clinicopathologic
factors. Odds ratios with 95% relative confidence intervals
were calculated to determine the relevance of all potential
predictors. A P value of < 0.05 was considered statistically
significant.
Results
The mean age of the 241 included patients was 43.9 ±
12.5 years (range 16 to 76 years), and the male to female
ratio was 1:2.6 (67:174). The mean primary tumor size
was 1.28 ± 0.97 cm. Multifocal and bilateral tumors were
found in 84 (34.9%) and 44 (18.3%) patients, respectively.Most of the primary tumor lesions showed capsular in-
vasion (79.3%). Thyroiditis was observed in 71 patients
(29.5%), metastases to the central compartment in 173
patients (71.8%), and skip LNMs in 68 patients (28.2%).
The mean maximal positive lymph node size by patho-
logic determination was 0.91 ± 0.62 cm (range 0.01 to
3.8 cm; Table 1).
Of the 241 patients, 51 (21.2%) had SLNM and 190
(78.8%) had MLNM. Table 2 shows the demographic
and pathologic characteristics of the two groups. Mean
primary tumors were significantly smaller in patients with
SLNM than in patients with MLNM (1.03 ± 0.59 cm ver-
sus 1.35 ± 1.05 cm; P = 0.037). Of the 51 patients with
SLNM, 31 (60.8%) had primary tumors ≤ 1 cm in size.
Capsular invasion was significantly less frequent (62.7%
versus 83.7%; P = 0.002), whereas skip LNMs were signifi-
cantly more frequently II (39.2% versus 25.3%; P = 0.049),
in the SLNM than in the MLNM group. The mean max-
imal size of metastatic nodes was lower in the SLNM
than in the MLNM group (0.40 ± 0.38 cm versus 1.03 ±
0.60 cm; P < 0.001). Using a cutoff of 0.7 cm, the meta-
static node size had a positive predictive value of 40.2%
and a negative predictive value of 91.7% for predicting
the presence of SLNM. This maximal metastatic node
size had a specificity of 76.5% and a sensitivity of 69.4%. A
receiver operating characteristics curve relating maximal
Table 2 Comparisons of clinicopathologic variables
between the solitary (SLNM) and multiple (MLNM) lateral
compartment metastases
Variables Lateral compartment metastasis P
valueGroup I
(SLNM)
Group II
(MLNM)
(n = 51) (n = 190)
Age (years) 42.9 ± 12.0 44.2 ± 12.7 0.526
≥ 45 18 (35.3%) 90 (47.4%) 0.154
< 45 33 (64.7%) 100 (52.66%)
Sex (male/female) 14 (27.5%)/
37 (72.5%)
53 (27.9%)/
137 (72.1%)
0.950
Tumor size (cm) 1.03 ± 0.59 1.35 ± 1.05 0.037
> 1 cm 20 (39.2%) 117 (61.6%) 0.006
≤ 1 cm 31 (60.8%) 73 (38.4%)
Multifocality 211 (41.2%) 63 (33.2%) 0.322
Bilaterality 10 (19.6%) 34 (17.9%) 0.839
Thyroiditis 14 (27.5%) 57 (30.0%) 0.863
Capsular invasion 32 (62.7%) 159 (83.7%) 0.002
Harvested lateral
neck node
29.4 ± 11.0 30.3 ± 9.5 0.574
Central compartment
metastases
31 (60.8%) 142 (74.7%) 0.049
Skip metastasis 20 (39.2%) 48 (25.3%) 0.049
Maximal lymph
node size (cm)
0.40 ± 0.38 1.03 ± 0.60 <0.001
> 0.7 12 (23.5%) 132 (69.5%) < 0.001
≤ 0.7 39 (76.5%) 58 (30.5%)
Figure 1 Receiver operating characteristic (ROC) curve for
maximal metastatic node size and capsular invasion in the
prediction of solitary lateral neck metastasis.
Table 3 Multivariate analysis of the association between
multiple metastasis and clinicopathologic variables
Variable Odds ratio
(95% confidence interval)
P value
Tumor variables
Size (> 1 cm versus ≤ 1 cm) 1.810 (0.743 to 4.412) 0.192
Capsular invasion 1.952 (0.923 to 4.126) 0.039
Lymph node variables
Central metastases 1.824 (0.739 to 4.506) 0.193
Maximal lymph node size 5.805 (2.540 to 13.270) <0.001
(> 0.7 cm versus ≤ 0.7 cm)
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There were no significant differences in age, sex, multifo-
cality, or bilaterality between the SLNM and MLNM
groups, and the numbers of lateral neck nodes harvested
per patient were similar in the two groups. Logistic regres-
sion analysis revealed that capsular invasion of primary
tumor and maximal metastatic node size > 0.7 cm were in-
dependent predictors of MLNM (Table 3). The distribution
of SLNM according to primary tumor location is shown in
Table 4. The highest incidence of SLNM was at level III
(52.9%). None of the patients with primary tumors in the
lower pole had SLNMs at level II.
Discussion
Cervical lymph node metastasis from PTC is common
[1-5]. Although it remains unclear whether lymph node
metastasis is associated with mortality, the risk of lymph
node recurrence is thought to be increased when cer-
vical lymph node metastasis is found at the time of diag-
nosis [1,9-11,13-15]. Re-operation for disease recurrence
in the neck contributes to increased operative morbidity
and medical costs [16-18]. Thus, surgeons should alwaysperform a thorough preoperative evaluation for lymph
node metastasis to determine the exact extent of neck dis-
section. The types of neck dissection in patients requiring
LND include selective compartment, ipsilateral, and bilat-
eral modified radical neck dissection [5,12,14,19]. Whether
performed for diagnostic or therapeutic purposes, the role
of LND is highly dependent on the metastatic pattern in
lateral neck nodes. To our knowledge, this study is the first
to provide information on the characteristics of primary
PTCs in patients with SLNM. We hypothesized that the
clinicopathologic features of the primary tumor may help
predict the risk of SLNM and decrease the extent of LND,
without increasing lateral neck recurrences.
Male gender, larger tumor size, T4 stage, and pathologic
central lymph node metastasis have been found to in-
crease the likelihood of LNM [1,3,4,20,21]. Our univariate
Table 4 Distribution of solitary lateral neck metastasis
according to primary tumor location
Neck level
number
Upper
n = 9 (%)
Mid
n = 26 (%)
Lower
n = 16 (%)
Total
2 3 (33.3%) 2 (7.6%) 0 (0%) 5 (9.8%)
3 3 (33.3%) 12 (46.2%) 12 (75.0%) 27 (52.9%)
4 3 (33.3%) 12 (46.2%) 4 (25.0%) 19 (37.3%)
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capsular invasion by the primary tumor and maximal
node diameter ≤ 0.7 cm were significantly associated with
SLNM. It is difficult to evaluate these factors by pre-
operative imaging methods, such as ultrasonography
and computed tomography. However, intraoperative fro-
zen sectioning of the primary tumor and metastatic lateral
neck nodes can determine capsular invasion and lymph
node size.
LNM is believed to occur initially in the central com-
partment and then spread to the lateral compartment
[2,3,22-24]. Skip metastasis is thought to be a rare sub-
phenomenon. Although skip metastasis occurs in only a
small number of patients, it defeats the purpose of onco-
logic surgery and may result in disseminated distant me-
tastases. We found that skip metastasis was more common
in patients with SLNM than in those with MLNM, in
agreement with our previous results [22].
Routes of lymphatic drainage in patients with PTC are
both patient- and lesion-specific due to complicated
lymphatic streams from the thyroid. The neck level at
which metastasis is most frequent has been analyzed by
subdividing tumor locations. For example, level II was
the most frequent in patients with upper pole tumors,
whereas levels III and IV were the most frequent in pa-
tients with lower and mid-pole tumors [16]. We found
that 52.9% of patients with SLNM had metastases at
level III. We observed no relationship between meta-
static rates and neck level in patients with upper pole tu-
mors, whereas metastases to level III nodes were more
frequent in patients with lower and mid-pole tumors.
One limitation of this study was that we enrolled pa-
tients who underwent non-prophylactic but therapeutic
LND. It is not possible to determine the true incidence
of LNM in patients with PTC. The true incidence of
LNM may affect the clinicopathologic features predict-
ing SLNM. However, the decision to perform LND is
usually based on clinical evidence for LNM. Although
we evaluated clinically relevant nodal status that required
initial LND, it is unclear whether prophylactic LND
improves the prognosis of patients with PTC [19,25].
In contrast, clinically overt lymph node metastasis in the
lateral compartment is a strong indicator of poor progno-
sis, and therapeutic LND has been recommended for pa-
tients with node metastases detected by ultrasonography[26-29]. Western guidelines therefore do not recommend
prophylactic dissection of the lateral compartment [27].
Low-risk PTC had an excellent prognosis and a low
mortality rate [6,13,15,17,29]. The treatment of it could be
only thyroidectomy without node dissection [30]. Still, a
proportion of patients with small tumors will experience
recurrent or persistent disease. Careful risk stratification
makes it possible to individualize treatment, avoiding
unnecessary procedures, and guarantees a good long-
term prognosis with a low recurrence risk. In this study,
the SLNM group showed low-risk PTC characteristics in
terms of small primary tumor size and no extrathyroidal
extension.
Conclusions
Our findings indicate that selective single level neck dissec-
tion can be considered an alternative to systemic LND in
PTC patients with SLNM, maximal metastatic node size ≤
0.7 cm, and no evidence of extrathyroidal invasion.
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